EGFR and neoplasm: To find why patients with multiple alterations (the ALL_M and EGFR_M group) had better survival outcomes compared to the patients with single EGFR alteration (the ALL_S and the EGFR_S group) after immunotherapy, we investigated the fractions of tumor‐infiltrated immune cells (TIICs) between these groups in the TCGA cohort.